title: Conventional induction treatments do not influence overall survival in multiple myeloma.
abstract: A retrospective analysis was performed on two subsequent myeloma patient series treated with the same conventional induction treatments, melphalan and prednisone or alternating VMCP/VBAP: 273 were enrolled in the multicentre M83 trial (M83 trial group) from 1983 to 1986; 160 were referred to a single institution (Haemat. To group) from 1986 to 1994. Response to treatment was very similar in the two groups (53% v 50.3%). Remission duration curves merely overlapped (median 20 v 21 months). However, overall survival was significantly longer in the Haemat. To group (43.2 v 33 months, P < 0.04). This difference was due to a prolonged period from relapse or progression to death (21 v 8 months, P < 0.01; 20.8 v 7 months, P < 0.009). Prolonged survival was also observed in poor-prognosis patients with a serum beta2-microglobulin level > 3 mg/l, in the Haemat. To group (31.8 v 24.2 months, P < 0.04). The same induction treatments produced almost identical response rate and remission duration in both groups, but overall survival was 10 months longer for one group. However, it could be argued that treatment salvage modalities and support therapies have been improved in a decade. Lastly, induction treatments did not influence overall survival.
authors.affiliation: Dipartimento di Medicina ed Oncologia Sperimentale, Azienda Ospedaliera San Giovanni, Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Boccadoro
authors.forename: A
authors.initials: A
authors.lastname: Palumbo
authors.forename: C
authors.initials: C
authors.lastname: Argentino
authors.forename: A
authors.initials: A
authors.lastname: Dominietto
authors.forename: R
authors.initials: R
authors.lastname: Frieri
authors.forename: G
authors.initials: G
authors.lastname: Avvisati
authors.forename: B
authors.initials: B
authors.lastname: Comotti
authors.forename: V M
authors.initials: VM
authors.lastname: Lauta
authors.forename: M
authors.initials: M
authors.lastname: Liberati
authors.forename: F
authors.initials: F
authors.lastname: Marmont
authors.forename: P
authors.initials: P
authors.lastname: Musto
authors.forename: M
authors.initials: M
authors.lastname: Tribalto
authors.forename: A
authors.initials: A
authors.lastname: Pileri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone